As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma||585||
|Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma||811||
|A Study of Pembrolizumab in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma||059||
||Phase 2||Active, not recruiting|
|A Study of Pembrolizumab Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine||061||
||Phase 3||Active, not recruiting|
|Study of Pembrolizumab as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma||062||Gastric Adenocarcinoma||Phase 3||Active, not recruiting|
|Study of Pembrolizumab Plus Chemotherapy in Participants with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma||859||Stomach Neoplasms||Phase 3||Not yet recruiting|